

Page 2
Serial No. 09/786,648
August 12, 2003

In the Specification

Page 6, line 6

C1 The substance substance of the present invention is capable of acting in a manner that is the same as or is similar to EtxB and/or CtxB.

Page 9, Lines 1-9 (by single spaces)

C2 As used herein, the term "immunomodulator" means a substance that is capable of modulating the immune response by including, for example, a differential effect on cells, such as lymphocyte cells - preferably leading to induction of apoptosis in CD8+ T cells and/or enhanced activation of CD4+ cells and/or the polyclonal activation ~~fo~~of B cells.

Page 36, lines 18-26

C3 Examples of infectious disease of the present invention include but are not limited to HSV-1, HSV-2, EBV, VZV, CMV, HHV-6, HHV-7, and HHV-8, hepatitis A, B, C, D and E, *Neisseria meningitidis*, *Haemophilus influenzae* type B and *Streptococcus pneumoniae*, *Legionella pneumophila* and *Mycobacterium tuberculosis*, *Neisseria gonorrhoeae*, HIV-1, HIV-2 and *Chlamydia trachomatis*, *E.coli*, rotavirus, *Salmonella enteritidis*, *Salmonella typhi*, *Helicobacter pylori*, *Bacillus cereus*, *Campylobacter jejuni* and *Vibrio cholerae*, *Staphylococcus aureus*, *Streptococcus pyogenes* and *Streptococcus mutans*, *malaria*, *Trypanasoma spp.*, *Taxoplasma gondii*, *Leishmania donovani*, and *Oncocerca spp.*